|
1
|
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
|
Lancet Oncol
|
2012
|
5.82
|
|
2
|
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
|
J Clin Oncol
|
2005
|
4.03
|
|
3
|
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
|
Clin Cancer Res
|
2004
|
2.90
|
|
4
|
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
2.62
|
|
5
|
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.
|
J Immunol
|
2004
|
2.44
|
|
6
|
Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment.
|
Lung Cancer
|
2008
|
2.37
|
|
7
|
Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
2.09
|
|
8
|
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
|
Cancer
|
2012
|
1.84
|
|
9
|
Chemotherapy use and associated factors among cancer patients near the end of life.
|
Oncology
|
2007
|
1.80
|
|
10
|
Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies.
|
Cancer
|
2004
|
1.71
|
|
11
|
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.
|
Breast Cancer Res
|
2011
|
1.69
|
|
12
|
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
|
BMC Cancer
|
2007
|
1.68
|
|
13
|
Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.
|
Lung Cancer
|
2012
|
1.58
|
|
14
|
MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma.
|
Clin Cancer Res
|
2011
|
1.54
|
|
15
|
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
|
Clin Cancer Res
|
2006
|
1.53
|
|
16
|
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
|
Int J Cancer
|
2005
|
1.52
|
|
17
|
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).
|
Oncologist
|
2014
|
1.50
|
|
18
|
Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters.
|
Cancer Biol Ther
|
2006
|
1.46
|
|
19
|
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
|
J Thorac Oncol
|
2015
|
1.44
|
|
20
|
Palliative chemotherapy for pulmonary pleomorphic carcinoma.
|
Lung Cancer
|
2007
|
1.40
|
|
21
|
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study).
|
Leuk Lymphoma
|
2014
|
1.40
|
|
22
|
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
|
J Thorac Oncol
|
2013
|
1.39
|
|
23
|
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
|
Jpn J Clin Oncol
|
2002
|
1.34
|
|
24
|
Aggressiveness of cancer-care near the end-of-life in Korea.
|
Jpn J Clin Oncol
|
2008
|
1.29
|
|
25
|
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
|
Lung Cancer
|
2007
|
1.29
|
|
26
|
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
|
Lung Cancer
|
2008
|
1.28
|
|
27
|
Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory.
|
Oncology
|
2004
|
1.25
|
|
28
|
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type.
|
Blood
|
2005
|
1.24
|
|
29
|
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
|
Lung Cancer
|
2012
|
1.23
|
|
30
|
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
|
Lung Cancer
|
2012
|
1.21
|
|
31
|
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
|
J Thorac Oncol
|
2013
|
1.20
|
|
32
|
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
|
Cancer
|
2011
|
1.17
|
|
33
|
The role of PET/CT in detection of gastric cancer recurrence.
|
BMC Cancer
|
2009
|
1.16
|
|
34
|
The attitudes of cancer patients and their families toward the disclosure of terminal illness.
|
J Clin Oncol
|
2004
|
1.15
|
|
35
|
Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study.
|
Jpn J Cancer Res
|
2002
|
1.14
|
|
36
|
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
|
BMC Cancer
|
2007
|
1.13
|
|
37
|
CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience.
|
Support Care Cancer
|
2005
|
1.12
|
|
38
|
Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone.
|
Jpn J Clin Oncol
|
2003
|
1.12
|
|
39
|
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
|
BMC Cancer
|
2008
|
1.11
|
|
40
|
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.
|
J Neurooncol
|
2011
|
1.11
|
|
41
|
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
|
Breast Cancer Res Treat
|
2008
|
1.09
|
|
42
|
Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines.
|
Tumour Biol
|
2008
|
1.08
|
|
43
|
Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma.
|
Acta Oncol
|
2003
|
1.06
|
|
44
|
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
|
Lung Cancer
|
2008
|
1.06
|
|
45
|
Attitudes of cancer patients, family caregivers, oncologists and members of the general public toward critical interventions at the end of life of terminally ill patients.
|
CMAJ
|
2011
|
1.05
|
|
46
|
Experiences and attitudes of patients with terminal cancer and their family caregivers toward the disclosure of terminal illness.
|
J Clin Oncol
|
2010
|
1.05
|
|
47
|
Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
|
J Thorac Oncol
|
2011
|
1.04
|
|
48
|
Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies.
|
Cancer Sci
|
2009
|
1.03
|
|
49
|
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
|
Laryngoscope
|
2008
|
1.03
|
|
50
|
EGFR mutations as a predictive marker of cytotoxic chemotherapy.
|
Lung Cancer
|
2012
|
1.03
|
|
51
|
Chylothorax in Gorham's disease.
|
J Korean Med Sci
|
2002
|
1.03
|
|
52
|
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
|
BMC Cancer
|
2008
|
1.03
|
|
53
|
Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
1.01
|
|
54
|
Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study.
|
Support Care Cancer
|
2012
|
0.99
|
|
55
|
Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
0.97
|
|
56
|
Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study.
|
J Clin Oncol
|
2011
|
0.97
|
|
57
|
Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
|
J Thorac Oncol
|
2013
|
0.97
|
|
58
|
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
|
Lung Cancer
|
2006
|
0.97
|
|
59
|
Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
|
Head Neck
|
2009
|
0.96
|
|
60
|
Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
|
Clin Lung Cancer
|
2013
|
0.96
|
|
61
|
EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units.
|
Support Care Cancer
|
2005
|
0.96
|
|
62
|
A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.
|
Oncol Rep
|
2004
|
0.95
|
|
63
|
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy.
|
J Cancer Res Clin Oncol
|
2011
|
0.95
|
|
64
|
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
|
Jpn J Clin Oncol
|
2004
|
0.94
|
|
65
|
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
|
Int J Clin Oncol
|
2013
|
0.93
|
|
66
|
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
|
Jpn J Clin Oncol
|
2006
|
0.93
|
|
67
|
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
|
Lung Cancer
|
2011
|
0.93
|
|
68
|
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer.
|
Oncol Rep
|
2005
|
0.93
|
|
69
|
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
|
Leuk Lymphoma
|
2014
|
0.93
|
|
70
|
Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
|
J Thorac Oncol
|
2015
|
0.93
|
|
71
|
GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.
|
PLoS One
|
2013
|
0.92
|
|
72
|
Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.
|
Cancer
|
2004
|
0.91
|
|
73
|
First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
|
Leuk Lymphoma
|
2006
|
0.91
|
|
74
|
CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function.
|
Tumour Biol
|
2011
|
0.89
|
|
75
|
Impact of caregivers' unmet needs for supportive care on quality of terminal cancer care delivered and caregiver's workforce performance.
|
Support Care Cancer
|
2009
|
0.89
|
|
76
|
Health economics of a palliative care unit for terminal cancer patients: a retrospective cohort study.
|
Support Care Cancer
|
2010
|
0.88
|
|
77
|
Clinical dissection of multicentric Castleman disease.
|
Leuk Lymphoma
|
2011
|
0.88
|
|
78
|
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
|
Pharmacogenet Genomics
|
2007
|
0.88
|
|
79
|
PPARγ ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells.
|
Biochem Biophys Res Commun
|
2011
|
0.88
|
|
80
|
Use of a decision aid to help caregivers discuss terminal disease status with a family member with cancer: a randomized controlled trial.
|
J Clin Oncol
|
2011
|
0.88
|
|
81
|
First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors.
|
Cancer Sci
|
2010
|
0.88
|
|
82
|
Multicenter study of pain and its management in patients with advanced cancer in Korea.
|
J Pain Symptom Manage
|
2003
|
0.87
|
|
83
|
Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.
|
BMC Cancer
|
2009
|
0.87
|
|
84
|
Life-sustaining medical treatment for terminal patients in Korea.
|
J Korean Med Sci
|
2013
|
0.87
|
|
85
|
Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
|
Am J Clin Oncol
|
2012
|
0.87
|
|
86
|
The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives.
|
Support Care Cancer
|
2012
|
0.87
|
|
87
|
Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer.
|
Radiat Oncol J
|
2013
|
0.87
|
|
88
|
Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
|
Ann Hematol
|
2014
|
0.86
|
|
89
|
Irradiated and activated autologous PBMCs induce expansion of highly cytotoxic human NK cells in vitro.
|
J Immunother
|
2013
|
0.86
|
|
90
|
Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
|
Cancer
|
2003
|
0.86
|
|
91
|
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
|
Jpn J Clin Oncol
|
2005
|
0.86
|
|
92
|
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
|
Int J Oncol
|
2012
|
0.85
|
|
93
|
A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.
|
Cancer
|
2004
|
0.85
|
|
94
|
A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer.
|
Am J Clin Oncol
|
2002
|
0.85
|
|
95
|
Awareness of incurable cancer status and health-related quality of life among advanced cancer patients: a prospective cohort study.
|
Palliat Med
|
2011
|
0.85
|
|
96
|
Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.
|
Leuk Lymphoma
|
2013
|
0.84
|
|
97
|
Factors influencing preferences for place of terminal care and of death among cancer patients and their families in Korea.
|
Support Care Cancer
|
2005
|
0.84
|
|
98
|
Artificial nutrition and hydration in terminal cancer patients: the real and the ideal.
|
Support Care Cancer
|
2006
|
0.84
|
|
99
|
Presence of membrane-bound TGF-beta1 and its regulation by IL-2-activated immune cell-derived IFN-gamma in head and neck squamous cell carcinoma cell lines.
|
J Immunol
|
2009
|
0.84
|
|
100
|
Safety of comprehensive aortic root and valve repair surgery: a retrospective outcomes research by national evidence-based health care collaborating agency, Korea.
|
Korean Circ J
|
2012
|
0.84
|
|
101
|
Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer.
|
Cancer Invest
|
2008
|
0.84
|
|
102
|
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial.
|
J Neurooncol
|
2010
|
0.84
|
|
103
|
EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma.
|
Jpn J Clin Oncol
|
2011
|
0.84
|
|
104
|
Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients.
|
Anticancer Res
|
2003
|
0.83
|
|
105
|
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
|
J Neurooncol
|
2013
|
0.83
|
|
106
|
Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer.
|
Cancer Sci
|
2011
|
0.83
|
|
107
|
Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines.
|
Int J Mol Med
|
2009
|
0.83
|
|
108
|
Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities.
|
Leuk Lymphoma
|
2014
|
0.83
|
|
109
|
Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma.
|
Ann Hematol
|
2014
|
0.83
|
|
110
|
A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma.
|
Neuro Oncol
|
2013
|
0.83
|
|
111
|
International comparison of the factors influencing reimbursement of targeted anti-cancer drugs.
|
BMC Health Serv Res
|
2014
|
0.82
|
|
112
|
Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
|
Neuropathology
|
2009
|
0.82
|
|
113
|
Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging.
|
J Neurooncol
|
2013
|
0.82
|
|
114
|
Herpes simplex virus thymidine kinase and granulocyte macrophage colony-stimulating factor combination gene therapy in a murine CT26 cell colon cancer model.
|
Cancer Gene Ther
|
2004
|
0.82
|
|
115
|
Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients.
|
Cancer Res Treat
|
2012
|
0.82
|
|
116
|
Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer.
|
Lung Cancer
|
2003
|
0.82
|
|
117
|
Comparative analysis of NK/T-cell lymphoma and peripheral T-cell lymphoma in Korea: Clinicopathological correlations and analysis of EBV strain type and 30-bp deletion variant LMP1.
|
Pathol Int
|
2003
|
0.82
|
|
118
|
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
|
Leuk Lymphoma
|
2015
|
0.81
|
|
119
|
Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line.
|
Oncol Rep
|
2010
|
0.81
|
|
120
|
Solitary squamous cell carcinoma in the kidney after metachronous development of esophageal and lung cancer.
|
Tumori
|
2005
|
0.81
|
|
121
|
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
|
Clin Cancer Res
|
2006
|
0.81
|
|
122
|
Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme.
|
J Neurooncol
|
2002
|
0.81
|
|
123
|
Complementary and alternative medicine use among cancer patients at the end of life: Korean national study.
|
Asian Pac J Cancer Prev
|
2012
|
0.81
|
|
124
|
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
|
Lung Cancer
|
2009
|
0.81
|
|
125
|
Upfront chemotherapy and involved-field radiotherapy results in more relapses than extended radiotherapy for intracranial germinomas: modification in radiotherapy volume might be needed.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.80
|
|
126
|
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer.
|
J Cancer Res Clin Oncol
|
2014
|
0.80
|
|
127
|
Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study.
|
Jpn J Clin Oncol
|
2010
|
0.80
|
|
128
|
Discrepancies in performance status scores as determined by cancer patients and oncologists: are they influenced by depression?
|
Gen Hosp Psychiatry
|
2007
|
0.80
|
|
129
|
A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta1.
|
Tumori
|
2011
|
0.80
|
|
130
|
Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas.
|
BMC Cancer
|
2014
|
0.80
|
|
131
|
Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.
|
Jpn J Clin Oncol
|
2005
|
0.80
|
|
132
|
Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy.
|
Oral Surg Oral Med Oral Pathol Oral Radiol
|
2013
|
0.79
|
|
133
|
Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.
|
Cancer Sci
|
2009
|
0.79
|
|
134
|
Patient-reported assessment of quality care at end of life: development and validation of Quality Care Questionnaire-End of Life (QCQ-EOL).
|
Eur J Cancer
|
2006
|
0.79
|
|
135
|
Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients.
|
Cancer Res Treat
|
2004
|
0.79
|
|
136
|
Effect of advanced cancer patients' awareness of disease status on treatment decisional conflicts and satisfaction during palliative chemotherapy: a Korean prospective cohort study.
|
Support Care Cancer
|
2011
|
0.79
|
|
137
|
How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution.
|
Cancer Res Treat
|
2013
|
0.79
|
|
138
|
Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy.
|
Support Care Cancer
|
2011
|
0.78
|
|
139
|
Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.
|
Cancer Res Treat
|
2008
|
0.78
|
|
140
|
Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.
|
J Korean Med Sci
|
2006
|
0.78
|
|
141
|
Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis.
|
J Cancer Res Clin Oncol
|
2014
|
0.78
|
|
142
|
Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center.
|
Hematology
|
2011
|
0.78
|
|
143
|
Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers.
|
Cytotherapy
|
2013
|
0.78
|
|
144
|
Factors associated with place of death in koprean patients with terminal cancer.
|
Asian Pac J Cancer Prev
|
2013
|
0.77
|
|
145
|
Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients.
|
Lung Cancer
|
2008
|
0.77
|
|
146
|
A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with α fetoprotein as a predictive and prognostic marker.
|
Mol Med Rep
|
2011
|
0.77
|
|
147
|
The life-sustaining treatments among cancer patients at end of life and the caregiver's experience and perspectives.
|
Support Care Cancer
|
2009
|
0.77
|
|
148
|
Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer.
|
J Korean Med Sci
|
2007
|
0.77
|
|
149
|
Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
|
Ann Hematol
|
2009
|
0.77
|
|
150
|
Targeted therapy of DNA tumor virus-associated cancers using virus-activated transcription factors.
|
Mol Ther
|
2006
|
0.77
|
|
151
|
Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.
|
Lung Cancer
|
2006
|
0.77
|
|
152
|
Colorectal cancer in Korea: characteristics and trends.
|
Tumori
|
2002
|
0.77
|
|
153
|
Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma.
|
Cancer Res Treat
|
2014
|
0.77
|
|
154
|
Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer.
|
Thromb Haemost
|
2014
|
0.77
|
|
155
|
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.
|
J Cancer Res Clin Oncol
|
2014
|
0.76
|
|
156
|
Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation.
|
BMC Cancer
|
2011
|
0.76
|
|
157
|
Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data.
|
J Breast Cancer
|
2012
|
0.76
|
|
158
|
Seizures during the management of high-grade gliomas: clinical relevance to disease progression.
|
J Neurooncol
|
2013
|
0.76
|
|
159
|
Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma.
|
Leuk Lymphoma
|
2013
|
0.76
|
|
160
|
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
|
Eur J Cancer
|
2012
|
0.76
|
|
161
|
Invasion of the great vessels or atrium predicts worse prognosis in thymic carcinoma.
|
Radiat Oncol J
|
2013
|
0.76
|
|
162
|
Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma.
|
Cancer Sci
|
2011
|
0.76
|
|
163
|
Survey of controversial issues of end-of-life treatment decisions in Korea: similarities and discrepancies between healthcare professionals and the general public.
|
Crit Care
|
2013
|
0.75
|
|
164
|
A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC.
|
Tumour Biol
|
2010
|
0.75
|
|
165
|
Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment.
|
Acta Otolaryngol Suppl
|
2007
|
0.75
|
|
166
|
VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.
|
Diagn Mol Pathol
|
2011
|
0.75
|
|
167
|
Histologic transformation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
|
J Clin Oncol
|
2013
|
0.75
|
|
168
|
Survival of all cancer patients in Korea through 2-year follow-up.
|
J Korean Med Sci
|
2002
|
0.75
|
|
169
|
Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
|
Jpn J Clin Oncol
|
2005
|
0.75
|
|
170
|
Cancer Gene Therapy: Limitations and Progress.
|
Cancer Res Treat
|
2003
|
0.75
|
|
171
|
A Multi-Center, Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Cisplatin for Patients with Non-Small Cell Lung Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
|
172
|
Measuring the structure and process of end-of-life care in Korea: validation of the Korean version of the Care Evaluation Scale (CES).
|
J Pain Symptom Manage
|
2012
|
0.75
|
|
173
|
The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
|
Jpn J Clin Oncol
|
2012
|
0.75
|
|
174
|
Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer.
|
Lung Cancer
|
2009
|
0.75
|
|
175
|
Induction chemotherapy followed by radiotherapy in the treatment of anal cancer.
|
Oncol Rep
|
2002
|
0.75
|
|
176
|
Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis.
|
Chemotherapy
|
2009
|
0.75
|
|
177
|
Nonsurgical treatment of an incompletely excised primary adenocarcinoma of nonpigmented ciliary epithelium.
|
Tumori
|
2007
|
0.75
|
|
178
|
Factors influencing decision making on therapeutic interventions.
|
Int J Technol Assess Health Care
|
2013
|
0.75
|
|
179
|
Neoadjuvant chemotherapy followed by radiotherapy in epidermoid carcinoma of anus.
|
Tumori
|
2004
|
0.75
|